The Board of Directors of Gufic Biosciences Limited, at its meeting held on Saturday, November 14, 2026, approved the appointment of Dr. Reeta Shah (DIN: 07141304) as an Additional Director in the category of Non-Executive Independent Director.

Key Details of the Appointment

  • Effective Date: The appointment is effective from December 01, 2026.
  • Term: This is her first term, which is for a period of 5 consecutive years.
  • Condition: The appointment is subject to the approval of the company's shareholders.
  • Status Confirmation: The disclosure confirms that Dr. Reeta Shah is not debarred from holding the office of Director by virtue of any SEBI or other authority order.

Profile of the Appointee

Dr. Reeta Shah is a Chartered Accountant holding a Ph.D. in Finance from IIT Bombay, an LL.B. degree, and three Master's degrees. She possesses over 38 years of experience in the fields of Finance, Education, and Administration. Her professional background includes holding leadership positions at SIES College and ITM EEC, and she has been associated with premier institutions such as IIT Bombay, IIT Delhi, and IIM Indore. She previously served as an Independent Director at Shemaroo Entertainment Limited for a period of 10 years. She is also a TEDx speaker, international keynote speaker, growth strategist, and an active panelist and trainer at conferences and seminars organized by the ICAI and other reputed institutions.

Other Disclosures

  • Relationship with other Directors: It is disclosed that Dr. Reeta Shah is not related to any other director of the company.
  • Board Meeting Timing: The meeting of the Board of Directors commenced at 5:00 p.m. and concluded at 6:35 p.m. on November 14, 2026.
  • Regulatory Compliance: The required details under Regulation 30 of the SEBI LODR Regulations, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, were provided in an enclosed annexure (Annexure B).

The company secretary and compliance officer, Ami Shah (Membership No. A39579), digitally signed and submitted this disclosure to the BSE and NSE.